199 related articles for article (PubMed ID: 33627416)
1. Enhancement of liver-directed transgene expression at initial and repeat doses of AAV vectors admixed with ImmTOR nanoparticles.
Ilyinskii PO; Michaud AM; Roy CJ; Rizzo GL; Elkins SL; Capela T; Chowdhury AC; Leung SS; Kishimoto TK
Sci Adv; 2021 Feb; 7(9):. PubMed ID: 33627416
[TBL] [Abstract][Full Text] [Related]
2. ImmTOR nanoparticles enhance AAV transgene expression after initial and repeat dosing in a mouse model of methylmalonic acidemia.
Ilyinskii PO; Michaud AM; Rizzo GL; Roy CJ; Leung SS; Elkins SL; Capela T; Chowdhury A; Li L; Chandler RJ; Manoli I; Andres-Mateos E; Johnston LPM; Vandenberghe LH; Venditti CP; Kishimoto TK
Mol Ther Methods Clin Dev; 2021 Sep; 22():279-292. PubMed ID: 34485611
[TBL] [Abstract][Full Text] [Related]
3. Readministration of high-dose adeno-associated virus gene therapy vectors enabled by ImmTOR nanoparticles combined with B cell-targeted agents.
Ilyinskii PO; Roy C; Michaud A; Rizzo G; Capela T; Leung SS; Kishimoto TK
PNAS Nexus; 2023 Nov; 2(11):pgad394. PubMed ID: 38024395
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of the Tolerogenic Phenotype in the Liver by ImmTOR Nanoparticles.
Ilyinskii PO; Roy CJ; LePrevost J; Rizzo GL; Kishimoto TK
Front Immunol; 2021; 12():637469. PubMed ID: 34113339
[TBL] [Abstract][Full Text] [Related]
5. Development of ImmTOR Tolerogenic Nanoparticles for the Mitigation of Anti-drug Antibodies.
Kishimoto TK
Front Immunol; 2020; 11():969. PubMed ID: 32508839
[TBL] [Abstract][Full Text] [Related]
6. Rescue of infant progressive familial intrahepatic cholestasis type 3 mice by repeated dosing of AAV gene therapy.
Weber ND; Odriozola L; Ros-Gañán I; García-Porrero G; Salas D; Argemi J; Combal JP; Kishimoto TK; González-Aseguinolaza G
JHEP Rep; 2023 May; 5(5):100713. PubMed ID: 37096142
[TBL] [Abstract][Full Text] [Related]
7. Rapamycin nanoparticles increase the therapeutic window of engineered interleukin-2 and drive expansion of antigen-specific regulatory T cells for protection against autoimmune disease.
Kishimoto TK; Fournier M; Michaud A; Rizzo G; Roy C; Capela T; Nukolova N; Li N; Doyle L; Fu FN; VanDyke D; Traber PG; Spangler JB; Leung SS; Ilyinskii PO
J Autoimmun; 2023 Oct; 140():103125. PubMed ID: 37844543
[TBL] [Abstract][Full Text] [Related]
8. Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration.
Meliani A; Boisgerault F; Hardet R; Marmier S; Collaud F; Ronzitti G; Leborgne C; Costa Verdera H; Simon Sola M; Charles S; Vignaud A; van Wittenberghe L; Manni G; Christophe O; Fallarino F; Roy C; Michaud A; Ilyinskii P; Kishimoto TK; Mingozzi F
Nat Commun; 2018 Oct; 9(1):4098. PubMed ID: 30291246
[TBL] [Abstract][Full Text] [Related]
9. Autophagy determines efficiency of liver-directed gene therapy with adeno-associated viral vectors.
Hösel M; Huber A; Bohlen S; Lucifora J; Ronzitti G; Puzzo F; Boisgerault F; Hacker UT; Kwanten WJ; Klöting N; Blüher M; Gluschko A; Schramm M; Utermöhlen O; Bloch W; Mingozzi F; Krut O; Büning H
Hepatology; 2017 Jul; 66(1):252-265. PubMed ID: 28318036
[TBL] [Abstract][Full Text] [Related]
10. Immune responses to adeno-associated virus vectors.
Zaiss AK; Muruve DA
Curr Gene Ther; 2005 Jun; 5(3):323-31. PubMed ID: 15975009
[TBL] [Abstract][Full Text] [Related]
11. B cell focused transient immune suppression protocol for efficient AAV readministration to the liver.
Rana J; Herzog RW; Muñoz-Melero M; Yamada K; Kumar SRP; Lam AK; Markusic DM; Duan D; Terhorst C; Byrne BJ; Corti M; Biswas M
Mol Ther Methods Clin Dev; 2024 Mar; 32(1):101216. PubMed ID: 38440160
[TBL] [Abstract][Full Text] [Related]
12. Enhanced liver gene transfer and evasion of preexisting humoral immunity with exosome-enveloped AAV vectors.
Meliani A; Boisgerault F; Fitzpatrick Z; Marmier S; Leborgne C; Collaud F; Simon Sola M; Charles S; Ronzitti G; Vignaud A; van Wittenberghe L; Marolleau B; Jouen F; Tan S; Boyer O; Christophe O; Brisson AR; Maguire CA; Mingozzi F
Blood Adv; 2017 Oct; 1(23):2019-2031. PubMed ID: 29296848
[TBL] [Abstract][Full Text] [Related]
13. Influence of Pre-existing Anti-capsid Neutralizing and Binding Antibodies on AAV Vector Transduction.
Fitzpatrick Z; Leborgne C; Barbon E; Masat E; Ronzitti G; van Wittenberghe L; Vignaud A; Collaud F; Charles S; Simon Sola M; Jouen F; Boyer O; Mingozzi F
Mol Ther Methods Clin Dev; 2018 Jun; 9():119-129. PubMed ID: 29766022
[TBL] [Abstract][Full Text] [Related]
14. Adeno-associated virus (AAV) capsid engineering in liver-directed gene therapy.
Rodríguez-Márquez E; Meumann N; Büning H
Expert Opin Biol Ther; 2021 Jun; 21(6):749-766. PubMed ID: 33331201
[No Abstract] [Full Text] [Related]
15. Ocular Inflammatory Response to Intravitreal Injection of Adeno-Associated Virus Vector: Relative Contribution of Genome and Capsid.
Timmers AM; Newmark JA; Turunen HT; Farivar T; Liu J; Song C; Ye GJ; Pennock S; Gaskin C; Knop DR; Shearman MS
Hum Gene Ther; 2020 Jan; 31(1-2):80-89. PubMed ID: 31544533
[TBL] [Abstract][Full Text] [Related]
16. Transient and intensive pharmacological immunosuppression fails to improve AAV-based liver gene transfer in non-human primates.
Unzu C; Hervás-Stubbs S; Sampedro A; Mauleón I; Mancheño U; Alfaro C; de Salamanca RE; Benito A; Beattie SG; Petry H; Prieto J; Melero I; Fontanellas A
J Transl Med; 2012 Jun; 10():122. PubMed ID: 22704060
[TBL] [Abstract][Full Text] [Related]
17. Gene Transfer in Adeno-Associated Virus Seropositive Rhesus Macaques Following Rapamycin Treatment and Subcutaneous Delivery of AAV6, but Not Retargeted AAV6 Vectors.
Stone D; Kenkel EJ; Loprieno MA; Tanaka M; De Silva Feelixge HS; Kumar AJ; Stensland L; Obenza WM; Wangari S; Ahrens CY; Murnane RD; Peterson CW; Kiem HP; Huang ML; Aubert M; Hu SL; Jerome KR
Hum Gene Ther; 2021 Jan; 32(1-2):96-112. PubMed ID: 32998579
[TBL] [Abstract][Full Text] [Related]
18. Preclinical models to assess the immunogenicity of AAV vectors.
Ertl HCJ
Cell Immunol; 2019 Aug; 342():103722. PubMed ID: 29195742
[TBL] [Abstract][Full Text] [Related]
19. Circumventing B Cell Responses to Allow for Redosing of Adeno-Associated Virus Vectors.
Ertl HCJ
Hum Gene Ther; 2023 Dec; ():. PubMed ID: 37861281
[TBL] [Abstract][Full Text] [Related]
20. Tolerogenic nanoparticles mitigate the formation of anti-drug antibodies against pegylated uricase in patients with hyperuricemia.
Sands E; Kivitz A; DeHaan W; Leung SS; Johnston L; Kishimoto TK
Nat Commun; 2022 Jan; 13(1):272. PubMed ID: 35022448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
